trial

Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.

NCTId NCT00945503
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2008-12-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2008-05-19
Primary completion
2008-12-22
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
GSK1018921

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Barcelona, Spain

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2008-12-22
Status
COMPLETED
relationships
The graph out of here
drug
GSK1018921
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication